{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:33:53Z","timestamp":1792103633927,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-026-00821-7","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:02:01Z","timestamp":1780045321000},"page":"565-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipoprotein(a) and oxidized phospholipids are associated with myocardial inflammation after acute myocardial infarction"],"prefix":"10.1038","volume":"5","author":[{"given":"Mark","family":"Atallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Valenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia S.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Gerstenblith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2569-6617","authenticated-orcid":false,"given":"Thorsten M.","family":"Leucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"821_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","volume":"21","author":"S Tsimikas","year":"2024","unstructured":"Tsimikas, S. & Witztum, J. L. Oxidized phospholipids in cardiovascular disease. Nat. Rev. Cardiol. 21, 170\u2013191 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"821_CR2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/art.24448","volume":"60","author":"A Kadl","year":"2009","unstructured":"Kadl, A., Galkina, E. & Leitinger, N. Induction of CCR2-dependent macrophage accumulation by oxidized phospholipids in the air-pouch model of inflammation. Arthritis Rheum. 60, 1362\u20131371 (2009).","journal-title":"Arthritis Rheum."},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.freeradbiomed.2017.02.035","volume":"111","author":"V Serbulea","year":"2017","unstructured":"Serbulea, V., DeWeese, D. & Leitinger, N. The effect of oxidized phospholipids on phenotypic polarization and function of macrophages. Free Radic. Biol. Med. 111, 156\u2013168 (2017).","journal-title":"Free Radic. Biol. Med."},{"key":"821_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa, M. B. & Koschinsky, M. L. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 16, 305\u2013318 (2019).","journal-title":"Nat. Rev. Cardiol."},{"key":"821_CR5","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney, N. J. et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388, 2239\u20132253 (2016).","journal-title":"Lancet"},{"key":"821_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamacardio.2024.5433","volume":"10","author":"RS Rosenson","year":"2025","unstructured":"Rosenson, R. S. et al. Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial. JAMA Cardiol. 10, 482\u2013486 (2025).","journal-title":"JAMA Cardiol."},{"key":"821_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jacc.2025.07.064","volume":"86","author":"A Imbesi","year":"2025","unstructured":"Imbesi, A. et al. Targeting inflammation after acute myocardial infarction. J. Am. Coll. Cardiol. 86, 1146\u20131169 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"821_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo, L., Rocha-Resende, C., Prabhu, S. D. & Mann, D. L. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 17, 269\u2013285 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"821_CR9","doi-asserted-by":"publisher","first-page":"120469","DOI":"10.1016\/j.atherosclerosis.2025.120469","volume":"409","author":"M Atallah","year":"2025","unstructured":"Atallah, M. et al. Oxidized phospholipid dynamics in the early post-infarction period: effects of PCSK9 inhibition with evolocumab. Atherosclerosis 409, 120469 (2025).","journal-title":"Atherosclerosis"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","volume":"171","author":"MA Vavuranakis","year":"2022","unstructured":"Vavuranakis, M. A. et al. The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition. Am. J. Cardiol. 171, 1\u20136 (2022).","journal-title":"Am. J. Cardiol."},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jacbts.2025.03.010","volume":"10","author":"E Ziogos","year":"2025","unstructured":"Ziogos, E. et al. Impact of in-hospital PCSK9 inhibition on myocardial inflammation after myocardial infarction: a randomized clinical trial. JACC Basic Transl. Sci. 10, 709\u2013720 (2025).","journal-title":"JACC Basic Transl. Sci."},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.jacc.2025.08.101","volume":"86","author":"HS Bhatia","year":"2025","unstructured":"Bhatia, H. S. et al. Association of lipoprotein(a) and interleukin-6 with cardiovascular risk: MESA and UK Biobank. J. Am. Coll. Cardiol. 86, 2000\u20132013 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"821_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/cvr\/cvy136","volume":"115","author":"C Yeang","year":"2019","unstructured":"Yeang, C. et al. Reduction of myocardial ischaemia\u2013reperfusion injury by inactivating oxidized phospholipids. Cardiovasc. Res. 115, 179\u2013189 (2019).","journal-title":"Cardiovasc. Res."},{"key":"821_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.626842","volume":"12","author":"M Di Gioia","year":"2021","unstructured":"Di Gioia, M. & Zanoni, I. Dooming phagocyte responses: inflammatory effects of endogenous oxidized phospholipids. Front. Endocrinol. 12, 626842 (2021).","journal-title":"Front. Endocrinol."},{"key":"821_CR15","doi-asserted-by":"publisher","first-page":"E6254","DOI":"10.1073\/pnas.1800544115","volume":"115","author":"V Serbulea","year":"2018","unstructured":"Serbulea, V. et al. Macrophage phenotype and bioenergetics are controlled by oxidized phospholipids identified in lean and obese adipose tissue. Proc. Natl Acad. Sci. USA 115, E6254\u2013E6263 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"821_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00674","volume":"11","author":"M Zhao","year":"2020","unstructured":"Zhao, M., Wang, D. D. H., Liu, X. & Tian, R. Metabolic modulation of macrophage function post myocardial infarction. Front. Physiol. 11, 674 (2020).","journal-title":"Front. Physiol."},{"key":"821_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02600-y","volume":"24","author":"R Xu","year":"2025","unstructured":"Xu, R., Wang, Z., Dong, J., Yu, M. & Zhou, Y. Lipoprotein(a) and panvascular disease. Lipids Health Dis. 24, 186 (2025).","journal-title":"Lipids Health Dis."},{"key":"821_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/01.RES.78.4.615","volume":"78","author":"LB Nielsen","year":"1996","unstructured":"Nielsen, L. B., Stender, S., Kjeldsen, K. & Nordestgaard, B. G. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ. Res. 78, 615\u2013626 (1996).","journal-title":"Circ. Res."},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jacbts.2023.10.007","volume":"9","author":"HW West","year":"2023","unstructured":"West, H. W., Dangas, K. & Antoniades, C. Advances in clinical imaging of vascular inflammation. JACC Basic Transl. Sci. 9, 710\u2013732 (2023).","journal-title":"JACC Basic Transl. Sci."},{"key":"821_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/CIRCIMAGING.108.846253","volume":"2","author":"R Lautam\u00e4ki","year":"2009","unstructured":"Lautam\u00e4ki, R. et al. Integration of infarct size, tissue perfusion, and metabolism by hybrid cardiac positron emission tomography\/computed tomography. Circ. Cardiovasc. Imaging 2, 299\u2013305 (2009).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"821_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01529-9","volume":"23","author":"A \u0106orovi\u0107","year":"2021","unstructured":"\u0106orovi\u0107, A., Nus, M., Mallat, Z., Rudd, J. H. F. & Tarkin, J. M. PET Imaging of post-infarct myocardial inflammation. Curr. Cardiol. Rep. 23, 99 (2021).","journal-title":"Curr. Cardiol. Rep."},{"key":"821_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004316","volume":"9","author":"C Rischpler","year":"2016","unstructured":"Rischpler, C. et al. Prospective evaluation of 18F-FDG uptake in post-ischemic myocardium by simultaneous pet\/mri as a prognostic marker of functional outcome. Circ. Cardiovasc. Imaging 9, e004316 (2016).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"821_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00395-024-01064-y","volume":"119","author":"D Lukovic","year":"2024","unstructured":"Lukovic, D. et al. Increased [18F]FDG uptake in the infarcted myocardial area displayed by combined PET\/CMR correlates with snRNA-seq-detected inflammatory cell invasion. Basic Res. Cardiol. 119, 807\u2013829 (2024).","journal-title":"Basic Res. Cardiol."},{"key":"821_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034774","volume":"13","author":"JL Januzzi Jr","year":"2024","unstructured":"Januzzi, J. L. Jr et al. Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study. J. Am. Heart Assoc. 13, e034774 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"821_CR25","doi-asserted-by":"crossref","unstructured":"Paruchuri, K. et al. Lipoprotein(a) and outcomes in worsening heart failure with preserved ejection fraction: the PARAGLIDE-HF trial. JACC Heart Fail. 14, 102843 (2025).","DOI":"10.1016\/j.jchf.2025.102843"},{"key":"821_CR26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1161\/CIRCULATIONAHA.125.073855","volume":"152","author":"S Tsimikas","year":"2025","unstructured":"Tsimikas, S. et al. Oxidized phospholipids, lipoprotein(a), and cardiovascular outcomes after acute coronary syndrome. Circulation 152, 1666\u20131678 (2025).","journal-title":"Circulation"},{"key":"821_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","volume":"78","author":"GG Schwartz","year":"2021","unstructured":"Schwartz, G. G. et al. Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol. J. Am. Coll. Cardiol. 78, 421\u2013433 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"821_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue, M. L. et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139, 1483\u20131492 (2019).","journal-title":"Circulation"},{"key":"821_CR29","doi-asserted-by":"publisher","first-page":"e70133","DOI":"10.1111\/eci.70133","volume":"56","author":"M Atallah","year":"2026","unstructured":"Atallah, M., Nasrallah, N., Harb, T., Gerstenblith, G. & Leucker, T. M. The biology of lipoprotein(a): from genetics to molecular mechanisms. Eur. J. Clin. Invest. 56, e70133 (2026).","journal-title":"Eur. J. Clin. Invest."},{"key":"821_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls, S. J. et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA 333, 222\u2013231 (2025).","journal-title":"JAMA"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen, S. E. et al. Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA 332, 1992\u20132002 (2024).","journal-title":"JAMA"},{"key":"821_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","volume":"142","author":"TM Leucker","year":"2020","unstructured":"Leucker, T. M. et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation 142, 419\u2013421 (2020).","journal-title":"Circulation"},{"key":"821_CR33","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ehjcvp\/pvad051","volume":"9","author":"E Ziogos","year":"2023","unstructured":"Ziogos, E. et al. Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition. Eur. Heart J. Cardiovasc. Pharmacother. 9, 636\u2013646 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"821_CR34","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","volume":"65","author":"YS Byun","year":"2015","unstructured":"Byun, Y. S. et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J. Am. Coll. Cardiol. 65, 1286\u20131295 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"821_CR35","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2021.07.031","volume":"78","author":"HS Bhatia","year":"2021","unstructured":"Bhatia, H. S. et al. PCSK9 Inhibition and Oxidized Phospholipids. J. Am. Coll. Cardiol. 78, 1288\u20131289 (2021).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00821-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00821-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00821-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:03:55Z","timestamp":1781618635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00821-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00821-7","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No specific funding was received for this analysis. Although prior related work by the authors has been supported by Amgen, the present study was conducted independently and without financial support from any commercial entity. T.M.L. has received research grant support from the National Heart, Lung, and Blood Institute (NHLBI), Merck, Novartis and Amgen, outside of and not relevant to the submitted work. S.T. is a co-inventor and receives royalties from patents owned by the University of California San Diego (UCSD), is a co-founder and has an equity interest in Oxitope and Kleanthi Diagnostics, and has a dual appointment at UCSD and Ionis Pharmaceuticals. The terms of this arrangement have been reviewed and approved by the UCSD in accordance with its conflict-of-interest policies. S.T. is supported by NHLBI grant nos. R01 HL159156 and HL170224. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}